You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

October 25, 2016

The Importance of Patents in Drug Tenders in Vietnam

Subscribe to Updates
Vietnam Pharma Update

With a population of over 90 million, fast-paced economic growth, and an increasing standard of living, Vietnam has become a market with great potential for original brand name drugs. These drugs are marketed through numerous channels, with drug tenders called by health facilities being one of the most prominent and profitable.

For drug tenders, an original brand name drug can be offered in either a bidding package for generic drugs or a bidding package for original brand name drugs. The latter is more lucrative, of course, due to the higher prices. However, to qualify for the more lucrative bidding package, the drug must first be included in one of the following lists issued by the Ministry of Health (MOH):

  • List of original brand name drugs;
  • List of drugs therapeutically equivalent to original brand name drugs; or
  • List of rare drugs.

As discussed below, for a company to get its drug added to the list of original brand name drugs in Vietnam, the most important factor is being able to prove that the drug is covered in the protection scope of a registered patent. This can be a difficult and time-consuming process without the assistance of an experienced patent expert in Vietnam.

Legal Background

Under Article 2.19 of the currently in force Law on Pharmacy of 2005, “brand name drugs” are defined as drugs with manufacturer-created trade names which differ from their international nonproprietary names or international generic names. There is no further definition, however, of “original brand name drugs.” This term appeared for the first time in Joint Circular No. 01/2012/TTLT-BYT-BTC of the Ministry of Health and Ministry of Finance, dated January 19, 2012, guiding tenders for drug procurement at health facilities (Joint Circular 01). According to Article 3.1 of Joint Circular 01, an “original brand name drug” is a drug permitted for circulation for the first time based on sufficient data regarding its quality, safety, and effectiveness. The same definition is retained under Circular No. 11/2016/TT-BYT, which took effect on July 1, 2016, and replaced Joint Circular 01 and the new Law on Pharmacy which is scheduled to take effect on January 1, 2017. Sometimes, such drugs are referred to as “innovator drugs.”

The procedural requirements for getting a drug recognized as an original brand name drug are found in Decision No. 2962/QD-BYT of the MOH dated August 22, 2012, providing interim guidance on the required documents for recognition of original brand name drugs, drugs with therapeutic equivalence to original brand name drugs, and drugs having documents on bioequivalence, as amended by Decision No. 1545/QD-BYT on May 8, 2013 (collectively, Decision 2962). Accordingly, applicants need to submit an application dossier to the MOH which includes:

  • The standard form requesting the MOH to recognize a drug as an original brand name drug;
  • The patent and an accompanying letter indicating the specific claims which protect the original brand name drug;
  • The patent license agreement if the applicant is not the patent holder;
  • A Certificate of Pharmaceutical Product, Free Sale Certificate, or Marketing Authorization; and
  • Other documents, as necessary.

It is very important to note the requirement of accurately indicating the specific claims of the patent protecting the original brand name drug. The subject of this granted patent, which can be valid or expired, must be: (1) an active compound, if the drug contains one active substance; (2) a combination (mixture) of active compounds, if the drug contains more than one active compound; or (3) a pharmaceutical composition or preparation or formulation for injection, infusion, ocular treatment, spray, implant, transdermal patch, or gel. In addition, this patent must have been granted by the patent office of Australia, Austria, Brazil, Canada, China, Europe, Finland, Germany, Israel, Japan, Korea, Russia, Spain, Sweden, the United Kingdom, the United States, or Vietnam.

Application dossiers will be examined by a special committee including patent experts from the National Office of Intellectual Property (NOIP) of Vietnam and pharmaceutical experts from the Drug Administration of Vietnam (DAV) under the MOH. Successfully registered drugs will be added to the lists of recognized original brand name drugs (also called “innovator lists” or “IP lists”) issued by the MOH. The first list of original brand name drugs was issued on January 11, 2013. As of August 23, 2016, the MOH has issued 15 lists including 1,041 original brand name drugs, of which three products have been removed.

The Challenge of Proving Patent Coverage

Under the procedural requirements of Decision 2962, it is clear that to be included in the list of “original brand name drugs,” a drug must have been granted a patent, even if that patent is not still valid, and that the granted patent must satisfy certain requirements of subject type and territory.

As a practical matter, the most important factor in getting recognition of original brand name drugs is proving that the subject drug falls within the protection scope of the patent(s) being referred to. A drug may relate to a number of patents granted in various jurisdictions, and therefore, it may be difficult for pharmaceutical companies to determine which patents are suitable for recognition purposes. Pharmaceutical companies are advised to follow the process below:

Step 1:  Choose patents granted by any of the 17 patent offices accepted for such purpose in Vietnam.

Step 2:  Screen these patents by reviewing the granted claim sets for the accepted subject types (i.e., compound, combination, or composition patents).

Step 3:  To prove that the patent(s) covers the drug, select a basic compound patent (for drugs with one active substance) or a combination patent (for drugs with two or more active substances).

For drugs containing active substances of a chemical nature whose relevant compound patents are characterized by names or structures of the compounds, registration dossiers are likely to go smoothly and will be accepted within about six months. For other drugs, especially biological drugs, the MOH is often very reluctant to examine their registration dossiers, leading to a delay. Therefore, applicants in those cases should submit detailed documentary references (e.g., claim analysis, reliable evidence for structures and other features of active substances in drugs, documents comparing each feature cited in particular claims to the corresponding feature of the active substances in the drugs and comments on the identicalness/similarity of these features, etc.). These references can be helpful in convincing the competent authority that the drugs are or were protected by particular claims in particular patents and to shorten the registration timeline.

Other challenges often arise in proving the chain of title to patents, especially in cases where patent holders have been merged or dissolved.

Summary

Being included in the list of original brand name drugs plays a vital role in tenders called by public health facilities. The later a drug is added to the list of original brand name drugs, the fewer opportunities it will have to participate in original brand name drug tenders. In other words, pharmaceutical companies may miss opportunities to build market share in Vietnam.

To improve the transparency and efficiency of drug tenders, the MOH should complete the legal regulations regarding procedural requirements for getting original brand name drugs recognized. Additionally, the NOIP and the DAV should cooperate to hold seminars or training courses to help pharmaceutical companies get a deeper understanding of patent aspects related to original brand name drug tenders. In the meantime, as a proactive step for their benefit, pharmaceutical companies should consider seeking appropriate assistance from patent experts to effectively handle their patent matters in getting their drugs recognized on the lists of original brand name drugs.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Corporate/M&A

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
Read More
July 24, 2026
For businesses in Thailand’s regulated industries, the problem of “too many licenses” is one of the most familiar hurdles to getting a product to market. Take a simple example: importing the materials necessary to sell teriyaki chicken skewers. To legally do this, a business may need approvals from several different agencies—separate permits for the chicken (Department of Livestock Development), the dipping sauce (Thai FDA), the wooden skewers (Department of Forestry), and other ingredients, each under a different authority. This kind of overlap is often cited to argue for a “regulatory guillotine”—a systematic review to cut outdated or duplicative rules that slow investment and business activity. The Facilitation of Licensing and Public Service Consideration Act B.E. 2569 (2026) (Licensing Facilitation Act 2026) is Thailand’s most significant response yet to that concern. This article looks at the Facilitation Act 2026 through a life sciences and regulatory affairs lens—what it may mean for the manufacturers, importers, and distributors of food, drugs, medical devices, cosmetics, and similar products who routinely deal with several regulators to bring a single product to market. The Super License: One Approval Standing in for Many The reform with the clearest potential for regulated-product businesses is the law’s “super license” mechanism, referred to as a “main license” in the statute. Once a business obtains the main license for a regulated activity, it is automatically deemed to hold all related sublicenses issued by other agencies for that same activity, provided the activity has been designated as eligible in the Government Gazette. The Licensing Facilitation Act 2026 also creates a central application center, allowing applicants to submit a single application and pay all relevant fees at one point of contact, with the center routing the application to each agency through a shared information system. The potential benefits of this for businesses
Read More
July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
Read More
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
Read More